Enhanced IgG immune response to COVID-19 vaccination in patients with sickle cell disease
© 2023 British Society for Haematology and John Wiley & Sons Ltd..
Patients with sickle cell disease (SCD) are considered to be immunocompromised, yet data on the antibody response to SARS-CoV-2 vaccination in SCD is limited. We investigated anti-SARS-CoV-2 IgG titres and overall neutralizing activity in 201 adults with SCD and demographically matched non-SCD controls. Unexpectedly, patients with SCD generate a more robust and durable COVID-19 vaccine IgG response compared to matched controls, though the neutralizing activity remained similar across both cohorts. These findings suggest that patients with SCD achieve a similar antibody response following COVID-19 vaccination compared to the general population, with implications for optimal vaccination strategies for patients with SCD.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:202 |
|---|---|
| Enthalten in: |
British journal of haematology - 202(2023), 5 vom: 07. Sept., Seite 937-941 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nakahara, Hirotomo [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 01.09.2023 Date Revised 12.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/bjh.18899 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM357889703 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357889703 | ||
| 003 | DE-627 | ||
| 005 | 20240312233053.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/bjh.18899 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1324.xml |
| 035 | |a (DE-627)NLM357889703 | ||
| 035 | |a (NLM)37287128 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Nakahara, Hirotomo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Enhanced IgG immune response to COVID-19 vaccination in patients with sickle cell disease |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.09.2023 | ||
| 500 | |a Date Revised 12.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 British Society for Haematology and John Wiley & Sons Ltd. | ||
| 520 | |a Patients with sickle cell disease (SCD) are considered to be immunocompromised, yet data on the antibody response to SARS-CoV-2 vaccination in SCD is limited. We investigated anti-SARS-CoV-2 IgG titres and overall neutralizing activity in 201 adults with SCD and demographically matched non-SCD controls. Unexpectedly, patients with SCD generate a more robust and durable COVID-19 vaccine IgG response compared to matched controls, though the neutralizing activity remained similar across both cohorts. These findings suggest that patients with SCD achieve a similar antibody response following COVID-19 vaccination compared to the general population, with implications for optimal vaccination strategies for patients with SCD | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a antibodies | |
| 650 | 4 | |a haemoglobinopathies | |
| 650 | 4 | |a immunology | |
| 650 | 4 | |a sickle cell anaemia | |
| 650 | 4 | |a sickle cell disease | |
| 650 | 4 | |a vaccines | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 700 | 1 | |a Cheedarla, Narayanaiah |e verfasserin |4 aut | |
| 700 | 1 | |a Verkerke, Hans P |e verfasserin |4 aut | |
| 700 | 1 | |a Cheedarla, Suneethamma |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Shang-Chuen |e verfasserin |4 aut | |
| 700 | 1 | |a Hendrickson, Jeanne E |e verfasserin |4 aut | |
| 700 | 1 | |a Chang, Andres |e verfasserin |4 aut | |
| 700 | 1 | |a McLemore, Morgan L |e verfasserin |4 aut | |
| 700 | 1 | |a El Rassi, Fuad |e verfasserin |4 aut | |
| 700 | 1 | |a Roback, John D |e verfasserin |4 aut | |
| 700 | 1 | |a Neish, Andrew S |e verfasserin |4 aut | |
| 700 | 1 | |a Fasano, Ross M |e verfasserin |4 aut | |
| 700 | 1 | |a Stowell, Sean R |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of haematology |d 1955 |g 202(2023), 5 vom: 07. Sept., Seite 937-941 |w (DE-627)NLM000000396 |x 1365-2141 |7 nnns |
| 773 | 1 | 8 | |g volume:202 |g year:2023 |g number:5 |g day:07 |g month:09 |g pages:937-941 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/bjh.18899 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 202 |j 2023 |e 5 |b 07 |c 09 |h 937-941 | ||